Literature DB >> 26133691

Programmed death-ligand 1, 2 expressions are decreased in the psoriatic epidermis.

Dae Suk Kim1, Jung Hwan Je, Sung Hee Kim, Dongyun Shin, Tae-Gyun Kim, Do Young Kim, Soo Min Kim, Min-Geol Lee.   

Abstract

Psoriatic keratinocytes are one of the key components that amplify and maintain chronic inflammation. We hypothesized that lack of proper regulatory functions of keratinocytes can be responsible for chronic inflammation in psoriasis. Programmed death-ligands (PD-L) 1, 2 are expressed on keratinocytes, and expressions by nonlymphoid cells are important for mediating peripheral T cell tolerance. In our study, we investigated whether PD-L1, 2 expressions are altered in keratinocytes of psoriatic epidermis compared to normal epidermis. Epidermis was separated and analyzed for PD-L1, 2 expressions in mRNA and protein levels. Immunohistochemical stainings were done in skin biopsy samples from psoriasis, normal skin, allergic contact dermatitis (ACD), pityriasis rosea (PR) and lichen planus (LP). Expressions of PD-L1, 2 mRNA levels were significantly decreased in psoriatic epidermis compared to normal epidermis. In protein levels, PD-L1 expression was significantly decreased in psoriatic epidermis. However, PD-L2 expression was not detected in both normal and psoriatic epidermis. Immunohistochemical stainings revealed significantly less PD-L1 expression in psoriatic epidermis compared to normal epidermis. Even compared to other cutaneous inflammatory diseases, psoriatic epidermis showed less expression than ACD, PR and LP. PD-L2 expression was minimally detected in normal epidermis and not in psoriatic epidermis, but its expression was increased in ACD, PR and LP. In conclusion, we demonstrated that PD-L1, 2 are decreased in psoriatic epidermis in mRNA and protein levels. In addition, we showed that their expression was significantly lower than other inflammatory skin diseases. We suggest that decreased expression of PD-L1, 2 on psoriatic epidermis can contribute to its chronic unregulated inflammatory characteristics.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26133691     DOI: 10.1007/s00403-015-1588-5

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  10 in total

1.  Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients.

Authors:  Myriam Delaunay; Jacques Cadranel; Amélie Lusque; Nicolas Meyer; Valérie Gounant; Denis Moro-Sibilot; Jean-Marie Michot; Judith Raimbourg; Nicolas Girard; Florian Guisier; David Planchard; Anne-Cécile Metivier; Pascale Tomasini; Eric Dansin; Maurice Pérol; Marion Campana; Oliver Gautschi; Martin Früh; Jean-David Fumet; Clarisse Audigier-Valette; Sébastien Couraud; Stéphane Dalle; Marie-Thérèse Leccia; Marion Jaffro; Samia Collot; Grégoire Prévot; Julie Milia; Julien Mazieres
Journal:  Eur Respir J       Date:  2017-08-10       Impact factor: 16.671

2.  Suppressed Programmed Death 1 Expression on CD4+ and CD8+ T Cells in Psoriatic Patients.

Authors:  Joanna Bartosińska; Ewelina Zakrzewska; Dorota Raczkiewicz; Joanna Purkot; Anna Michalak-Stoma; Małgorzata Kowal; Dorota Krasowska; Grażyna Chodorowska; Krzysztof Giannopoulos
Journal:  Mediators Inflamm       Date:  2017-10-17       Impact factor: 4.711

3.  Non-thermal atmospheric plasma ameliorates imiquimod-induced psoriasis-like skin inflammation in mice through inhibition of immune responses and up-regulation of PD-L1 expression.

Authors:  Yun Sang Lee; Myung-Hoon Lee; Hang-Jun Kim; Ho-Ryun Won; Chul-Ho Kim
Journal:  Sci Rep       Date:  2017-11-14       Impact factor: 4.379

4.  Gut microbiota restoration through fecal microbiota transplantation: a new atopic dermatitis therapy.

Authors:  Jong-Hwa Kim; Kiyoung Kim; Wonyong Kim
Journal:  Exp Mol Med       Date:  2021-05-20       Impact factor: 8.718

5.  Immunosuppressive Properties of Epidermal Keratinocytes Differ According to Their Immaturity Status.

Authors:  Guillaume Mestrallet; Edgardo D Carosella; Michele T Martin; Nathalie Rouas-Freiss; Nicolas O Fortunel; Joel LeMaoult
Journal:  Front Immunol       Date:  2022-02-11       Impact factor: 7.561

Review 6.  PD1/PD-L1 pathway in psoriasis and psoriatic arthritis: a review.

Authors:  Michał Adamczyk; Dorota Krasowska
Journal:  Postepy Dermatol Alergol       Date:  2022-01-07       Impact factor: 1.837

7.  Effect of baricitinib in regulating programmed death 1 and ligand programmed cell death ligand 1 through JAK/STAT pathway in psoriasis.

Authors:  H B Deepak; Sabina Evan Prince; Pratima Deshpande
Journal:  Indian J Pharmacol       Date:  2022 May-Jun       Impact factor: 2.833

8.  Indirubin attenuates mouse psoriasis-like skin lesion in a CD274-dependent manner: an achievement of RNA sequencing.

Authors:  Xiaochun Xue; Jianhua Wu; Junhui Li; Jianguo Xu; Haiying Dai; Congshan Tao; Chao Li; Jinhong Hu
Journal:  Biosci Rep       Date:  2018-11-23       Impact factor: 3.840

Review 9.  Inhibitory Receptors and Pathways of Lymphocytes: The Role of PD-1 in Treg Development and Their Involvement in Autoimmunity Onset and Cancer Progression.

Authors:  Elena Gianchecchi; Alessandra Fierabracci
Journal:  Front Immunol       Date:  2018-10-17       Impact factor: 7.561

10.  Atezolizumab-induced psoriasis in a patient with metastatic lung cancer-a case report.

Authors:  Mian Mao; Min Shi; Tao Li; Qifeng Wang; Lei Wu
Journal:  Transl Cancer Res       Date:  2020-05       Impact factor: 1.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.